## Correct Answer: B. Keratoconus The procedure shown is corneal cross-linking (CXL), a biomechanical stabilization technique that halts the progression of keratoconus. Keratoconus is a progressive, non-inflammatory corneal ectasia characterized by progressive thinning and cone-shaped deformation, leading to irregular astigmatism and vision loss. The hallmark pathophysiology involves loss of collagen cross-links and structural integrity of the corneal stroma. CXL works by inducing covalent bonds between collagen fibrils through riboflavin (vitamin B2) photosensitization and UVA irradiation (365 nm), thereby increasing corneal biomechanical rigidity and halting disease progression. In India, keratoconus is endemic (prevalence 0.5–4.6% in some regions), particularly in South India, making CXL a critical intervention. The procedure is indicated when keratoconus is progressing (evidenced by increasing keratometry readings, corneal topography changes, or refractive error progression over 6–12 months) and the cornea is thick enough (≥400 μm pachymetry) to safely undergo CXL without inducing scarring. CXL is the only intervention that can halt or slow progression; spectacles and contact lenses only correct refractive error but do not address the underlying biomechanical defect. Corneal transplantation remains reserved for advanced cases with scarring or severe visual impairment. ## Why the other options are wrong **A. Corneal dystrophy** — Corneal dystrophies are inherited, non-inflammatory, bilateral conditions affecting corneal clarity (e.g., lattice, granular, macular dystrophies). They do not cause progressive ectasia or cone deformation. CXL is not indicated for dystrophies; management focuses on lubricants, protective eyewear, or transplantation if vision is severely compromised. The biomechanical defect in dystrophies differs fundamentally from keratoconus. **C. Keratoglobus** — Keratoglobus is a rare, generalized corneal ectasia affecting the entire cornea (not localized cone), with corneal thinning and diffuse bulging. While both are ectasias, keratoglobus typically presents earlier in life with more severe thinning and is often associated with systemic conditions (Ehlers–Danlos, Marfan syndrome). CXL is contraindicated in keratoglobus due to severe corneal thinning (<400 μm), risk of perforation, and poor biomechanical response. Keratoglobus requires protective measures and early transplantation. **D. Vogt's limbal girdle** — Vogt's limbal girdle is a benign, age-related, bilateral deposition of lipid and calcium in the interpalpebral zone of the cornea, causing a horizontal band appearance. It does not affect corneal biomechanics, does not progress, and causes no functional vision loss. CXL is unnecessary; management is reassurance or cosmetic intervention if desired. This is a degenerative finding, not an ectatic disease requiring stabilization. ## High-Yield Facts - **Corneal cross-linking (CXL)** is the only intervention that halts or slows progression of keratoconus by increasing stromal collagen cross-links. - **Keratoconus prevalence in India** is 0.5–4.6%, particularly high in South India, making CXL a critical public health intervention. - **Pachymetry ≥400 μm** is mandatory before CXL to prevent corneal scarring and perforation; thinner corneas are contraindicated. - **Progression criteria** for CXL indication: increase in keratometry ≥1 D, refractive error change ≥1 D, or topographic changes over 6–12 months. - **Keratoglobus contraindication**: severe thinning (<400 μm) makes CXL unsafe; keratoglobus requires protective measures and early transplantation. - **Post-CXL outcome**: halts progression in 90–95% of cases; reversal of ectasia is rare but stabilization prevents need for transplantation in most patients. ## Mnemonics **CXL Indications: KERATO** **K**eratoconus (progressive) | **E**ctasia (ectatic disease) | **R**iboflavin + UVA (mechanism) | **A**t risk (halting progression) | **T**hick cornea (≥400 μm) | **O**nly biomechanical fix **When NOT to do CXL: THIN** **T**hin cornea (<400 μm) | **H**erpetic keratitis (contraindicated) | **I**nfection active | **N**on-ectatic disease (dystrophies, Vogt's girdle) ## NBE Trap NBE may pair keratoconus with corneal dystrophy to trap students who confuse inherited corneal pathology with acquired ectasia; dystrophies do not cause progressive cone deformation and do not require CXL. Similarly, NBE may conflate keratoglobus with keratoconus, but keratoglobus's severe thinning makes CXL contraindicated. ## Clinical Pearl In Indian clinical practice, keratoconus often presents in young patients (teens to 30s) with progressive myopia and astigmatism; early detection via topography and timely CXL can prevent the need for corneal transplantation, which carries significant morbidity and graft rejection risk in our population. CXL is now considered standard of care for progressive keratoconus in India. _Reference: Bailey & Love Ch. 28 (Cornea); Harrison Ch. 430 (Refractive errors and corneal disease)_
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.